ModuLife vs SmarTest Calprotectin

Please note: Access to the ModuLife platform is only available through participating trained healthcare providers. ModuLife is a virtual nutrition and wellness program supporting people with Crohn’s Disease. ModuLife is based on the Crohn’s Disease Exclusion Diet (CDED) designed for the dietary management of Crohn’s Disease. If you are interested in finding a ModuLife provider in your area, please visit MyModuLife.com. The ModuLife app provides exclusive access to educational tools, diet tracking, recipes, meal plans, messaging, and more. All of these features can be accessed on-the-go or from the convenience of your home. ON-DEMAND EDUCATION Get 24/7 access to educational videos and resources to support your ModuLife journey. TRACKING TOOLS Log food intake, diet adherence, and well-being to help you stay on track. MEAL PLANS View customized daily meal plans designed for your specific diet phase. RECIPES Access hundreds of easy-to-follow CDED-friendly recipes. UNLIMITED MESSAGING Ask for diet advice anytime through private instant messaging with nutrition specialists. Compatible with the Apple Health App to track activity. Users can sync with the Apple Health app via the ‘Devices & Settings’ tile. Once synced, users can view their steps from Apple’s Health app under the Wellness Tracker tile.

Reliable and simple app for quantitative determination of calprotectin in stool for in vitro diagnostic use. SmarTest Calprotectin is a manually performed rapid test including a smartphone app developed for its evaluation to quantitatively detect the inflammatory marker Calprotectin in human stool. It provides assistance in the follow-up and therapy monitoring of chronic inflammatory bowel diseases (e.g. Crohn's disease or ulcerative colitis). Calprotectin is a calcium-binding protein that is produced in large quantities by specific immune cells, the neutrophil granulocytes (neutrophils), and released during inflammatory events. In inflammatory bowel diseases, neutrophils migrate into the intestinal lumen and release calprotectin, which can then be detected in the stool. However, on the basis of clinical symptoms, it is often difficult to distinguish patients with inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis from patients suffering from the usual irritable bowel syndrome. With the additional determination of calprotectin in the stool, however, inflammation in the intestinal tract can be diagnosed with clinical certainty. An increased calprotectin concentration in the stool provides information about the presence of inflammation in the intestine. This non-invasive determination of calprotectin can often spare patients with common irritable bowel syndrome an unnecessary invasive colonoscopy in case of low concentrations. Since scientific studies have shown that the concentration of calprotectin in stool correlates well with histological and endoscopic findings of disease activity in patients with IBD, the calprotectin concentration in stool can also be used diagnostically to objectively document therapeutic success. Furthermore, it can be used to monitor currently asymptomatic IBD patients in order to detect and control relapse of IBD at an early stage.